Peregrine Pharmaceuticals (PPHM: Quote) announced the results from its internal review of discrepancies from its Phase II placebo-controlled trial of bavituximab in second-line non-small cell lung cancer in 121 patients Monday morning. The review indicates that discrepancies are isolated to the placebo and 1 mg/kg treatment arms of the trial and that there was no evidence of discrepancies in the 3 mg/kg treatment arm of the trial.
Peregrine Pharmaceuticals gapped open higher Monday and climbed throughout the first 2 hours of trade. Shares finished up by 1.08 at $2.43, with volume at over a 3-month high. The stock surged to its highest level since late September.
Click here to receive FREE breaking news email alerts for Peregrine Pharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org